Zacks Investment Research upgraded shares of Pharma Mar (OTCMKTS:PHMMF) from a sell rating to a hold rating in a research report report published on Wednesday, January 10th.
According to Zacks, “Pharma Mar SA is a biopharmaceutical company. It engaged in the discovery and development of marine-derived anticancer drugs. The company’s product pipeline consists of PM1183, plitidepsin, and PM184 which are in clinical trial stage. It operates primarily in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. Pharma Mar SA is headquartered in Madrid, Spain. “
Pharma Mar (OTCMKTS:PHMMF) opened at $2.15 on Wednesday. Pharma Mar has a 12-month low of $2.00 and a 12-month high of $4.80.
TRADEMARK VIOLATION WARNING: “Pharma Mar (PHMMF) Rating Increased to Hold at Zacks Investment Research” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/21/zacks-investment-research-upgrades-pharma-mar-phmmf-to-hold.html.
Pharma Mar Company Profile
Pharma Mar, SA, a biopharmaceutical company, engages in the discovery and development of marine-derived anticancer drugs in Spain and internationally. It develops and commercializes YONDELIS, a novel, multimodal, synthetically produced antitumor agent for the treatment of advanced soft tissue sarcomas as a single-agent, as well as for relapsed ovarian cancer in combination with Doxil/Caelyx.
Get a free copy of the Zacks research report on Pharma Mar (PHMMF)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pharma Mar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Mar and related companies with MarketBeat.com's FREE daily email newsletter.